All News
Curbside Consults - July 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases.
Read Article
FDA Approves Tremfya (guselkumab) for Plaque Psoriasis
The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.
Read Article
Orencia Approved for Use in Psoriatic Arthritis
The FDA has approved both IV and SC ORENCIA (abatacept) for the treatment of adults with active Psoriatic Arthritis.
Read Article
IV Golimumab in Psoriatic Arthritis
Based on recent clinical trials, the makers of golimumab have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.
Read Article
Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis
Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding. Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.
Read Article
Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial
Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).
Read Article
Inflammatory Arthritis Stable after Switch to Biosimilar Infliximab
The DANBIO registrys has demonstrated that switching from infliximab (Remicade) to biosimilar CT-P13 (Inflectra in the U.S., Remsima in Europe) does not appear to have any negative effect on inflammatory arthritis disease activity, Danish researchers reported.
Read Article
NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Read Article
The RheumNow Week in Review – 12 May 2017
Dr. Jack Cush highlights the big stories, news and articles from this week at RheumNow.com.
Read Article
FDA Approves Renflexis as Second Infliximab Biosimilar
On the 21st of April, the FDA approved another infliximab biosimilar, called Renflexis (Infliximab-abda) following on the biologics license application of the South Korean manufacturer Samsung Bioepis Co. LTD. In early developmental trials this agent was also called SB2.
Read Article
The RheumNow Week in Review – 14 April 2017
Dr. Jack Cush reviews the past week's news, articles and advances from RheumNow.com.
Read Article
The RheumNow Week in Review – 31 March 2017
Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:
Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.
Read Article
TNF Inhibitor Induced Psoriasis
Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.
Read Article
The RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review – 17 March 2017
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Read Article
The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read Article
Obesity Associated with Late-Onset Psoriatic Arthritis
A recent study reports that obesity is linked to late-onset psoriasis and psoriatic arthritis (PsA). By contrast being of normal weight may be associated with an earlier onset of the disease adn HLA-B27.
Read Article
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read Article
Immunosuppressives Fail to Benefit Early Skin Scleroderma
Treatment of systemic sclerosis is difficult, as there have few proven therapies capable of altering the course of the disease. Ideally, early intervention affords the optimal scenario wherein drug intervention can be proven to work.
Read Article
